WAWilliam Adams

William Adams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William Adams has a total of 292 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial

    by Abhishek A. Solanki, William Adams, James A. Proudfoot, Kristin Baldea, Güliz A. Barkan, Alec M. Block, Neil B. Desai, Ahmer Farooq, Michael R. Folkert, Aurelie Garant, et al.

    Purpose: Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. Methods: F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results: Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. Conclusion: DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.

  • Open Access

    Neuropsychiatric Symptom Associations with NOTCH3 Genotype in the United States CADASIL Consortium

    by Megan R. Caruso, Barbara L. Fischer, William H. Adams, Deven K. Burks, Bianca Le, Arash Salardini, Jennifer J. Majersik, Stephen P. Salloway, Jamie L. Elliott, H. Jeremy Bockholt, et al.

    Background and objectives: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic cerebral small vessel disease. Though neuropsychiatric symptoms (NPS) of CADASIL profoundly impact function and quality of life, these symptoms remain understudied. This analysis characterizes the prevalence, severity, and profile of NPS among individuals with CADASIL-causing NOTCH3 variants and non-carrier biological family controls in the United States CADASIL Consortium (USCC). Methods: This cross-sectional analysis used multimodal baseline data from 12 enrollment sites across the country. Statistical analyses used nonparametric tests and regression models to compare clinical and neuropsychiatric outcomes across CADASIL risk tiers and controls, adjusting for age, sex, race, and education where appropriate. The primary outcome measure was the Neuropsychiatric Inventory Questionnaire (NPI-Q), an informant-reported measure which assesses 12 categories of NPS. NPI-Q item severity and distress were evaluated for individuals with confirmed cysteine-altering pathogenic NOTCH3 variants and compared with controls. Results: Four hundred fifty-nine USCC participants were included in the analytic cohort: 343 cases [256 high-risk (HR); 63 medium-risk (MR); 24 low-risk (LR)]; and 116 controls. Among participants with available NPI-Q data, at least one neuropsychiatric symptom was reported by 72.6% (n = 228/314) of cases compared with 53.2% (n = 58/109) of controls. Reported symptoms were more common among CADASIL cases than controls, occurring in 75.0%, 71.2%, and 72.7% of participants in the LR, MR, and HR groups, respectively, compared with 53.2% of controls. Compared with controls, participants in the MR group and HR group had higher NPI-Q severity scores. HR participants also had higher NPI-Q distress scores than controls. Discussion: Our findings support the notion that NPS are an important clinical manifestation of CADASIL. Beyond previously reported symptoms, additional neuropsychiatric manifestations were identified. Given the higher burden and variability in the neuropsychiatric presentation of CADASIL, the relationships among neuropsychiatric, neurological, and patient-reported outcomes merit further investigation. The NPS profile may enhance the evaluation of the safety and efficacy of different treatments to target these symptoms for CADASIL patients. Trial Registration Information: The study is registered at ClinicalTrials.gov ( NCT05677880 , 12/12/2022).

  • Open Access

    The United States CADASIL Consortium: Baseline Findings from a Natural History Study

    by Jane S. Paulsen, H. Jeremy Bockholt, William H. Adams, Deven K. Burks, Jennifer J. Majersik, Stephen P. Salloway, Songmi Lee, Myriam Fornage, Cara Joyce, Jamie L. Elliott, et al.

    Background and Objectives: Vascular contributions to cognitive impairment and dementia (VCID) represent the second leading cause of dementia and a common comorbidity for reduced functional capacity in many individuals, but clinical management and clinical trial readiness are severely hindered by extreme phenotypic and mechanistic heterogeneity. This study establishes the baseline clinical, functional, and multimodal biomarker characteristics of the first United States (US) cohort of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), serving as a single-cause, monogenic small vessel disease model for sporadic VCID. Methods: Cross-sectional analysis of baseline data collected from October 2022 through January 2025 from a longitudinal cohort at 12 US enrollment sites. Adults from families with a documented NOTCH3 variant were recruited through clinical referrals, medical record review, advocacy organizations, and community outreach. Exclusion criteria included other conditions that prevented interpretation of findings and modified Rankin Scale (mRS) scores greater than 3. Central genetic characterization assigned persons with a pathogenic or likely pathogenic NOTCH3 variant to low-, medium-, or high-risk tiers based on epidermal growth factor-like repeat domains. Standardized assessments included clinical histories, exams, objective cognitive and physical assessments, self-reported, companion-reported, and clinician-rated measures, MRI, genetics, and proteomics acquired under harmonized protocols. Group comparisons used Fishers exact and Kruskal–Wallis tests. Multivariable regression used adjustment for age, sex, race, and education. Results: Of 560 participants completing baseline visits, 46 had variants of unknown significance, and 55 had pending genetic analyses. The analytic cohort included 343 persons with a CADASIL-causing NOTCH3 variant and 116 non-carrier family controls. Median age was 47.9 years (IQR 38.7–59.1), median education was 16 years (IQR 14– 17), 62.5% were female, and 91.4% were White. Carriers were classified in CADASIL risk tiers: low (7.0%), medium (18.4%), or high (74.6%). Compared with controls, adjusted odds of classification into a more impaired CDR category were higher in all tiers (OR 2.55-5.08, 95% CI 1.22–11.34). Discussion: The US CADASIL Consortium has established a large, genetics-confirmed cohort spanning presymptomatic to moderate disease stages, providing a robust, harmonized platform to define early biomarker signatures and endpoints for targeted VCID therapies.


  • Open Access

    Cerebrospinal Fluid Myeloperoxidase Is Associated With Putamen Volume Beyond Neurofilament Light in Huntington’s Disease

    by Jordan D. Clemsen, H. Jeremy Bockholt, William H. Adams, Bradley T. Baker, Jessica L. Bolton, Vince D. Calhoun, Jane S. Paulsen

    Background: The primary neuroanatomical site of Huntington’s disease (HD) pathology resides in the striatum and its atrophy identifies important disease progression from HD-ISS Stage 0 to Stage 1. Immune-associated proteins may capture variation in HD that is incompletely represented by markers of neuroaxonal injury. Objectives: To determine whether cerebrospinal-fluid myeloperoxidase contributes information about striatal volume loss beyond genetic disease burden and neurofilament light. Methods: Cross-sectional data from 88 persons with HD were analyzed. Cerebrospinal-fluid myeloperoxidase and neurofilament light were measured with a nucleic acid-linked immunosandwich assay. Normalized putamen volume was derived from structural magnetic resonance imaging. Linear regression adjusted for genetic disease burden and sex. Results: Higher neurofilament light was associated with smaller normalized putamen volume (standardized β = −0.322, (P=.0066)). Higher myeloperoxidase was associated with larger normalized putamen volume after adjustment for genetic disease burden, sex, and neurofilament light (standardized β = 0.183, (P=.0386)). Adding myeloperoxidase increased explained variance in striatal loss. Conclusions: Cerebrospinal fluid myeloperoxidase contributed modest incremental information about striatal volume in this cross-sectional sample. Independent longitudinal studies are needed to determine its biological source, temporal behavior, and potential biomarker value. Findings advance efforts to characterize multicomponent biological markers of HD.

  • Effects of a triple adjuvant combination of buprenorphine, clonidine, and dexamethasone on duration of brachial plexus blocks for upper extremity surgery: A prospective, randomized clinical trial

    by Nicholas Yonan, Samuel Mircoff, Sara Winfrey, William Adams, Julius Pawlowski, Legia Mondesir, John Jaworowicz, Umar Kamal, Dane Salazar, Nickolas Garbis, et al.

    Background: Interscalene brachial plexus blocks (ISB) are commonly used as a perioperative pain strategy for shoulder arthroscopy. Though bupivacaine is the current standard of care for analgesia, adjuvant therapies including buprenorphine, clonidine, and dexamethasone (BCD) have each demonstrated analgesic benefits. This randomized controlled trial evaluated whether combining these three adjuvants with bupivacaine prolongs analgesia and reduces opioid consumption compared with bupivacaine alone for single-shot ISB. Methods: This single-blinded, randomized controlled trial, 127 adult patients undergoing shoulder arthroscopy at a single academic center who received either Plain-BPV ( n = 66) or BPV-BCD ( n = 61). Visual analog scale (VAS) pain scores and opioid consumption, measured in morphine milligram equivalents (MME), were assessed at 2-, 24-, and 48-h postoperatively. Results: Demographics and operative characteristics were similar between groups. At 24 h, BPV-BCD significantly reduced pain scores compared with Plain-BPV (3.2 vs. 5.0 VAS; p < 0.001). Opioid consumption was also lower with BPV-BCD (4.4 vs. 7.8 MME; p = 0.001). Conclusions: Combining BCD with bupivacaine for single-shot ISB significantly lowered 24-h pain scores and opioid requirements. These findings highlight the potential efficacy of this combination to optimize pain management following shoulder arthroscopy.

  • Open Access

    One Dose Versus Two Doses of Intravenous Tranexamic Acid in Revision Total Joint Arthroplasty

    by Whisper Grayson, Anthony E. Seddio, Isaac Sontag-Milobsky, William H. Adams, Nicholas M. Brown

    Background: Tranexamic acid (TXA) is often used to reduce the amount of blood lost during total joint arthroplasty (TJA) and decrease the incidence of postoperative transfusion. Despite its extensive use, the ideal dosing regimen is still widely debated. The primary aims of this study were to compare single-dose and two-dose regimens on postoperative hemoglobin levels, transfusion rates, and 30-day complication rates in patients who underwent revision TJA. Methods: This retrospective study included patients who underwent revision total knee arthroplasty or revision total hip arthroplasty between April 2014 and November 2020 at a single academic institution. Patients were divided into two groups: One group received a 1 g bolus of intravenous TXA just before incision and another intravenous 1 g bolus during wound closure (n = 151), and the second group received a single, 1-g, intravenous bolus of TXA just before incision (n = 189). Results: No notable statistical differences were found between the two cohorts when evaluating postoperative hemoglobin levels (b = −0.18, 95% confidence interval [CI]: −0.39 to 0.03; P = 0.09), transfusion rates (odds ratio [OR] = 0.74, 95% CI: 0.39 to 1.38; P = 0.34), length of hospital stay (rate ratio = 0.95, 95% CI: 0.84 to 1.08; P = 0.43), and 30-day postoperative complication rates (OR = 1.30, 95% CI: 0.54 to 3.15; P = 0.56) even after controlling for patient characteristics and surgical factors. Conclusion: In this study, no association was found between a single dose of perioperative TXA during revision TJA and increased rates of post-operative complications when compared with two-doses, suggesting comparable efficacy.

  • Open Access

    Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients

    by Patricia Mumby, William Adams, Scott Smith, Murali Rao, Patrick Stiff


  • Locoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence

    by McKenzie Mosenthal, William Adams, Scott Cotler, Xianzhong Ding, Marc Borge, Angelo Malamis, David Lee, Tarita Thomas, Anugayathri Jawahar, Parag Amin, et al.


  • Open Access

    Emotional Intelligence and Resilience “PROGRAM” Improves Wellbeing and Stress Management Skills in Preclinical Medical Students

    by Julia L Versel, Alexandra Plezia, Lauren Jennings, Isaac Sontag-Milobsky, William Adams, Ramzan Shahid

    Purpose: The purpose of this study was to determine if implementation of a new educational curriculum focusing on Emotional Intelligence (EI) and Resilience improved second year medical student scores in these areas. Methods: Our EI-Resilience curriculum was offered as an elective for second year medical students to voluntarily enroll in. The elective consisted of six 2-hour sessions taught by a single faculty member over eight months. Sessions focused on development of EI skills and teaching a Resilience “PROGRAM” (Positive thinking, Reframing, Optimism, Gratitude, Reflection, Altruism, Meaning). Participants’ EI levels were assessed before and after the elective using the Bar-On Emotional Quotient Inventory 2.0 (EQ-i 2.0). Results: Over a period of 2 years, 70 students participated in the elective. The overall mean EI score significantly improved after the educational elective (100.05 ± 12.94 versus 108.14 ± 12.36, p < 0.001). Compared to the baseline scores, there was significant improvement in all EI components, including all five composite scales, all fifteen content subscales, and the well-being score (all p < 0.05). In a post-intervention survey assessing student perception of the elective, most students found the elective to be helpful (95%, 64/67), most students felt the elective should continue to be available for future students (95%, 64/67), and most would recommend the elective to other students (93%, 62/67). Conclusion: An EI-Resilience curriculum offered as an elective to second year medical students was well received by students. Our outcomes showed significant improvement in students’ EI scores and all sub-scores, including all components of the stress management composite and well-being score. Teaching EI skills and Resilience strategies in the preclinical setting might be an opportune time for this type of educational intervention.


  • Risk Factors for Persistent Lower Urinary Tract Symptoms 1 Month Following Convective Water Vapor Thermal Therapy (CWVTT-Rezum)

    by Sarang Janakiraman, Michael Felice, Gaurav Pahouja, William Adams, Aya Bsatee, Ahmer Farooq, Kevin T. McVary